FDA has become more cautious on drug safety, insiders say

11/14/2010 | Reuters

FDA officials seem to be taking a more cautious approach to drug evaluation after the agency restricted access to GlaxoSmithKline's diabetes pill Avandia because of heart risk, said industry executives and experts during the Reuters Health Summit. "There's no doubt in my mind that the FDA has become significantly more stringent in evaluating all drugs, especially diabetes drugs," Novo Nordisk CEO Lars Sorensen said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ